Richard G Moore

Summary

Affiliation: Women and Infants' Hospital
Country: USA

Publications

  1. ncbi request reprint Vulvar epithelioid sarcoma in pregnancy
    Richard G Moore
    Department of Obstetrics and Gynecology, Program in Women s Oncology, Brown University, Providence, Rhode Island 02905, USA
    Gynecol Oncol 85:218-22. 2002
  2. doi request reprint Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders
    Richard G Moore
    Center for Biomarkers and Emerging Technologies, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, RI 02905, USA
    Am J Obstet Gynecol 206:351.e1-8. 2012
  3. doi request reprint Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age
    Richard G Moore
    Center for Biomarkers and Emerging Technologies, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI 02905, USA
    Am J Obstet Gynecol 206:349.e1-7. 2012
  4. doi request reprint Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: a prospective trial
    Richard G Moore
    Program in Women s Oncology, Women and Infants Hospital, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 109:65-70. 2008
  5. pmc Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus
    Richard G Moore
    Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 110:196-201. 2008
  6. pmc A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
    Richard G Moore
    Program in Women s Oncology, Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 112:40-6. 2009
  7. pmc Current state of biomarker development for clinical application in epithelial ovarian cancer
    Richard G Moore
    Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI, USA
    Gynecol Oncol 116:240-5. 2010
  8. pmc Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass
    Richard G Moore
    Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, Warren Alpert Medical School, Brown University, Providence, RI, USA
    Am J Obstet Gynecol 203:228.e1-6. 2010
  9. doi request reprint Current clinical use of biomarkers for epithelial ovarian cancer
    Richard G Moore
    Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI 02905, USA
    Curr Opin Oncol 22:492-7. 2010
  10. doi request reprint Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus
    Richard G Moore
    Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI, USA
    Int J Gynecol Cancer 21:1185-90. 2011

Collaborators

Detail Information

Publications37

  1. ncbi request reprint Vulvar epithelioid sarcoma in pregnancy
    Richard G Moore
    Department of Obstetrics and Gynecology, Program in Women s Oncology, Brown University, Providence, Rhode Island 02905, USA
    Gynecol Oncol 85:218-22. 2002
    ..Vulvar sarcoma in pregnancy is also exceedingly rare with only five cases reported to date, none of which have been an epithelioid sarcoma...
  2. doi request reprint Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders
    Richard G Moore
    Center for Biomarkers and Emerging Technologies, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, RI 02905, USA
    Am J Obstet Gynecol 206:351.e1-8. 2012
    ..The human epididymis protein 4 (HE4) is a novel biomarker for ovarian cancer. This study measured the HE4 and CA125 levels in women with benign gynecological disorders...
  3. doi request reprint Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age
    Richard G Moore
    Center for Biomarkers and Emerging Technologies, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI 02905, USA
    Am J Obstet Gynecol 206:349.e1-7. 2012
    ..The purpose of this study was to establish normal ranges for human epididymis protein 4 (HE4) serum levels in healthy women...
  4. doi request reprint Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: a prospective trial
    Richard G Moore
    Program in Women s Oncology, Women and Infants Hospital, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 109:65-70. 2008
    ..The objective of this study was to examine the inguinal recurrence rate along with complication rates for patients undergoing inguinal SLN dissection alone for vulvar carcinoma...
  5. pmc Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus
    Richard G Moore
    Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 110:196-201. 2008
    ..The objectives of this study were to examine the levels of several novel tumor markers HE4, SMRP, CA72.4 and CA125 as potential markers in patients diagnosed with endometrioid adenocarcinoma of the uterus...
  6. pmc A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
    Richard G Moore
    Program in Women s Oncology, Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 112:40-6. 2009
    ..The objective of this trial was to validate a predictive model to assess the risk for EOC in women with a pelvic mass...
  7. pmc Current state of biomarker development for clinical application in epithelial ovarian cancer
    Richard G Moore
    Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI, USA
    Gynecol Oncol 116:240-5. 2010
    ..This review article will examine the current state of biomarker use in ovarian cancer screening, risk assessment and for monitoring ovarian cancer patients...
  8. pmc Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass
    Richard G Moore
    Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, Warren Alpert Medical School, Brown University, Providence, RI, USA
    Am J Obstet Gynecol 203:228.e1-6. 2010
    ..We sought to compare the Risk of Malignancy Index (RMI) to the Risk of Ovarian Malignancy Algorithm (ROMA) to predict epithelial ovarian cancer (EOC) in women with a pelvic mass...
  9. doi request reprint Current clinical use of biomarkers for epithelial ovarian cancer
    Richard G Moore
    Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI 02905, USA
    Curr Opin Oncol 22:492-7. 2010
    ..This review will focus on new biomarkers and algorithms for screening and risk assessment for ovarian cancer...
  10. doi request reprint Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus
    Richard G Moore
    Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI, USA
    Int J Gynecol Cancer 21:1185-90. 2011
    ....
  11. ncbi request reprint The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
    Richard G Moore
    Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 108:402-8. 2008
    ..Because elevated CA125 levels occur in many benign gynecologic conditions, we set out to identify other novel biomarkers that would increase the sensitivity and specificity of CA125...
  12. pmc Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass
    Richard G Moore
    Department of Obstetrics and Gynecology and the Center for Biomarkers and Emerging Technologies, Program in Women s Oncology, Women and Infants Hospital, Brown University, Providence, Rhode Island 02925, USA
    Obstet Gynecol 118:280-8. 2011
    ..The purpose of this study was to validate the Risk of Ovarian Malignancy Algorithm in women presenting with a pelvic mass...
  13. ncbi request reprint Sentinel node identification and the ability to detect metastatic tumor to inguinal lymph nodes in squamous cell cancer of the vulva
    Richard G Moore
    Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 89:475-9. 2003
    ....
  14. ncbi request reprint Pathologic evaluation of inguinal sentinel lymph nodes in vulvar cancer patients: a comparison of immunohistochemical staining versus ultrastaging with hematoxylin and eosin staining
    Richard G Moore
    Program in Women s Oncology, Department of Obstetrics and Gynecology, 101 Dudley Street, Women and Infants Hospital, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 91:378-82. 2003
    ..To evaluate the value of immunohistochemical (IHC) staining of inguinal sentinel lymph nodes (SLN) found to be negative for metastatic disease by ultrastaging with hematoxylin and eosin (H&E) staining...
  15. pmc Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI 02905, USA
    BMC Cancer 12:147. 2012
    ....
  16. ncbi request reprint Inguinal sentinel node dissection versus standard inguinal node dissection in patients with vulvar cancer: A comparison of the size of metastasis detected in inguinal lymph nodes
    Katina Robison
    Program in Women s Oncology, Women and Infants Hospital, Brown University, Providence, RI 02905 2499, USA
    Gynecol Oncol 101:24-7. 2006
    ..We hypothesize that the average size of metastasis detected in non-palpable inguinal lymph nodes is smaller when detected through the use of SLN dissection and ultra-staging versus complete inguinal node dissection (CND)...
  17. doi request reprint Description of the cytotoxic effect of a novel drug Abietyl-Isothiocyanate on endometrial cancer cell lines
    Timothy C Horan
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, 101 Dudley Street, Providence, RI 02905, USA
    Invest New Drugs 30:1460-70. 2012
    ..Key mechanisms during cell death are predominantly correlated to excess generation of ROS. We suggest the further development of ABITC as a potential therapeutic by studying the drug efficacy in EC in-vivo models...
  18. pmc Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment
    Donna Badgwell
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Box 355, 1515 Holcombe Boulevard, Houston, TX 77030, and Program in Women s Oncology, Women s and Infants Hospital, Providence, RI 02905, USA
    Gynecol Oncol 106:490-7. 2007
    ..Mesothelin has been detected in serum from patients with ovarian cancer, but has not been previously reported in urine...
  19. doi request reprint Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI, USA
    Gynecol Oncol 122:183-9. 2011
    ..This study tests the hypothesis that TM can modulate antioxidants in tumor cells and render doxorubicin resistant tumor cells sensitive to doxorubicin...
  20. doi request reprint The presence and location of epithelial implants and implants with epithelial proliferation may predict a higher risk of recurrence in serous borderline ovarian tumors: a clinicopathologic study of 188 cases
    M Ruhul Quddus
    Department of Pathology, Women and Infants Hospital, The Alpert Medical School of Brown University, Providence, RI 02905, USA
    Hum Pathol 43:747-52. 2012
    ..Although the anatomical location of such implants was not significantly associated with a higher risk, the presence of epithelial proliferation at multiple sites was more frequently seen in recurrent serous borderline ovarian tumors...
  21. doi request reprint Cytotoxic properties of Adamantyl isothiocyanate and potential in vivo metabolite adamantyl-N-acetylcystein in gynecological cancer cells
    Thilo S Lange
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, RI 02905, USA
    Chem Biol Drug Des 79:92-103. 2012
    ..We suggest the further development of adamantyl-N-acetylcystein by sensitizing cells to the drug using signaling inhibitors or redox-modulating agents and by evaluating the drug efficacy in ovarian and endometrial in-vivo tumor models...
  22. pmc Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model
    Richard G Moore
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, Alpert Medical School, Brown University, Providence, Rhode Island, United States of America
    PLoS ONE 7:e34443. 2012
    ..We identified the first non-hypercalcemic anti-cancer vitamin D analog MT19c by altering the A-ring of ergocalciferol. This study describes the therapeutic efficacy and mechanism of action of MT19c in both in vitro and in vivo models...
  23. doi request reprint Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, Providence, RI 02905, USA
    Int J Oncol 40:227-35. 2012
    ....
  24. doi request reprint 7 Methyl indole ethyl isothiocyanate causes ROS mediated apoptosis and cell cycle arrest in endometrial cancer cells
    Katrin Kristjansdottir
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, Alpert Medical School, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 126:252-8. 2012
    ..This study describes the therapeutic potential of 7 Methyl-indole ethyl isothiocyanate (7Me-IEITC) in endometrial cancer cell lines...
  25. doi request reprint Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines
    Laurent Brard
    Department of Obstetrics and Gynecology, Alpert Medical School, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 123:370-8. 2011
    ..This study was designed to evaluate a novel non-hypercalcemic vitamin-D derivative (MT19c) and its anticancer effects in cultured ovarian cancer cell model...
  26. pmc HE4 (WFDC2) gene overexpression promotes ovarian tumor growth
    Richard G Moore
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Women and Infants Hospital of Rhode Island, Alpert Medical School, Brown University, Providence, RI 02903, USA
    Sci Rep 4:3574. 2014
    ..Selective targeting directed towards the HE4 protein demonstrates therapeutic benefits for the treatment of ovarian cancer. ..
  27. ncbi request reprint Update on sentinel lymph node evaluation in gynecologic malignancies
    Katina Robison
    Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, USA
    Curr Opin Obstet Gynecol 23:8-12. 2011
    ..There has been increasing interest in the use of SLN technology in gynecologic cancers. This review assesses the current evidence-based literature for the use of SLN dissections in gynecologic malignancies...
  28. doi request reprint A case of Peutz-Jeghers syndrome with breast cancer, bilateral sex cord tumor with annular tubules, and adenoma malignum caused by STK11 gene mutation
    Aine Clements
    Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI, USA
    Int J Gynecol Cancer 19:1591-4. 2009
    ..This case report presents a patient with PJS with a concomitant breast cancer, bilateral stromal tumors with annular tubules of the ovaries, and adenoma malignum of the cervix...
  29. ncbi request reprint The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients
    Laurent Brard
    Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, 101 Dudley Street, Providence, RI 02905, USA
    Gynecol Oncol 103:176-80. 2006
    ..In this study, we compared survival from time of terminal intestinal obstruction (TIO) diagnosis in patients who received TPN versus those who did not...
  30. ncbi request reprint HPV vaccines--why aren't they the answer yet?
    Amy Kirkpatrick Brown
    Program in Women s Oncology, Women and Infants Hospital, Providence, RI 02905, USA
    Med Health R I 88:74-9. 2005
  31. ncbi request reprint Incidence of metastasis to the ovaries from nongenital tract primary tumors
    Richard G Moore
    Program in Women s Oncology, Department of Obstetrics and Gynecology, Woman and Infants Hospital Brown University, Providence, RI 02905, USA
    Gynecol Oncol 93:87-91. 2004
    ..The purpose of this study was to evaluate the characteristics of metastatic tumors to the ovaries in nongenital tract primaries and to determine the route of dissemination...
  32. pmc Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers
    Robert C Bast
    University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Gynecol Cancer 22:S5-8. 2012
    ..Both algorithms have high negative predictive values 94%-98%. Although a difference in specificity should not affect patient outcomes, it could affect distribution of medical resources...
  33. doi request reprint Vulvar encapsulated solid papillary carcinoma with neuroendocrine differentiation: a case report
    Cunxian Zhang
    Department of Pathology and Laboratory Medicine, Women and Infants Hospital of Rhode Island, Warren Alpert Medical School of Brown University, Providence, Rhode Island 02905, USA
    Int J Surg Pathol 20:97-100. 2012
    ..This is the first report of a vulvar encapsulated solid papillary carcinoma with neuroendocrine differentiation. Correct diagnosis is imperative because of the distinct biologic behavior of the tumor...
  34. pmc Organometallic iron(III)-salophene exerts cytotoxic properties in neuroblastoma cells via MAPK activation and ROS generation
    Kyu Kwang Kim
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, United States of America
    PLoS ONE 6:e19049. 2011
    ..We report here that Fe-SP is a potent growth-suppressing and cytotoxic agent for in vitro NB cell lines and, due to its high tolerance in previous animal toxicity studies, a potential therapeutic drug to treat NB tumors in vivo...
  35. doi request reprint Breast development and anatomy
    Sonali Pandya
    Program in Women s Oncology, Breast Health Center, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, USA
    Clin Obstet Gynecol 54:91-5. 2011
    ..Clinical breast examination can help to detect some cancers not found by mammography, and clinicians should not override their examination findings if imaging is not supportive of the physical findings...
  36. ncbi request reprint How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above
    Richard G Moore
    J Clin Oncol 25:4159-61. 2007
  37. ncbi request reprint Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer
    Mary E Gordinier
    Division of Gynecologic Oncology, University of Louisville Brown Cancer Center, 529 South Jackson Street, Louisville, KY 40202, USA
    J Palliat Med 10:61-6. 2007
    ....